X4 PHARMACEUTICALS INC's ticker is XFOR and the CUSIP is 98420X103. A total of 91 filers reported holding X4 PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,056 | -91.7% | 49,593 | -85.2% | 0.00% | – |
| Q2 2023 | $648,816 | +793.3% | 334,441 | +300.6% | 0.00% | – |
| Q1 2023 | $72,629 | +33.0% | 83,482 | +51.8% | 0.00% | – |
| Q4 2022 | $54,595 | -42.5% | 54,980 | -0.7% | 0.00% | – |
| Q3 2022 | $95,000 | +97.9% | 55,380 | +164.4% | 0.00% | – |
| Q4 2021 | $48,000 | -12.7% | 20,949 | +100.0% | 0.00% | – |
| Q3 2021 | $55,000 | -84.3% | 10,475 | -80.6% | 0.00% | – |
| Q2 2021 | $351,000 | -50.9% | 54,007 | -35.0% | 0.00% | – |
| Q1 2021 | $715,000 | +98.6% | 83,037 | +48.3% | 0.00% | – |
| Q4 2020 | $360,000 | +3.4% | 56,006 | +8.9% | 0.00% | – |
| Q3 2020 | $348,000 | +18.4% | 51,418 | +62.8% | 0.00% | – |
| Q2 2020 | $294,000 | +107.0% | 31,583 | +123.2% | 0.00% | – |
| Q1 2020 | $142,000 | -30.7% | 14,150 | -26.0% | 0.00% | – |
| Q4 2019 | $205,000 | +8.5% | 19,125 | +28.8% | 0.00% | – |
| Q3 2019 | $189,000 | -60.6% | 14,845 | -53.6% | 0.00% | – |
| Q2 2019 | $480,000 | – | 32,025 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 311,492 | $2,109,000 | 3.48% |
| SV Health Investors, LLC | 311,490 | $2,109,000 | 1.07% |
| Bain Capital Life Sciences Investors, LLC | 1,648,485 | $11,160,000 | 1.04% |
| New Leaf Venture Partners, L.L.C. | 335,000 | $2,268,000 | 0.91% |
| Ikarian Capital, LLC | 724,680 | $4,907,000 | 0.36% |
| BVF INC/IL | 792,892 | $5,368,000 | 0.29% |
| Opaleye Management Inc. | 75,000 | $508,000 | 0.10% |
| Orbimed Advisors | 1,086,493 | $7,356,000 | 0.09% |
| RA Capital Management | 559,494 | $3,788,000 | 0.07% |
| Bleichroeder LP | 35,730 | $242,000 | 0.04% |